Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 38,000 shares, a growth of 49.6% from the November 30th total of 25,400 shares. Currently, 0.8% of the company's stock are sold short. Based on an average trading volume of 8,400 shares, the days-to-cover ratio is presently 4.5 days.

Anebulo Pharmaceuticals Stock Down 6.8 %

ANEB stock opened at $2.42 on Friday. The firm has a 50 day moving average of $2.62 and a two-hundred day moving average of $3.17. Anebulo Pharmaceuticals has a 12 month low of $1.77 and a 12 month high of $7.89. The company has a market capitalization of $62.13 million, a price-to-earnings ratio of -7.13 and a beta of -1.48.

Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Rating) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter. On average, research analysts expect that Anebulo Pharmaceuticals will post -0.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Anebulo Pharmaceuticals Company Profile

(Get Rating)

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.

Featured Articles

• Get a free copy of the StockNews.com research report on Anebulo Pharmaceuticals (ANEB)
• MarketBeat: Week in Review 12/26 – 12/30
• The Dogs Of Tech: It's Time For A Bite Of These Stocks
• Does This Acquisition Make Microsoft a Bear Market Buy?
• Should You Warm up to Generac Stock for the Winter?
• Is Kintara Therapeutics A Hidden Gem?

Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.